Institutional investors purchased a net $737.1 thousand shares of RGEN during the quarter ended December 2012. This may signal that the smart money is gaining interest in this company as the 54.83% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
| Other institutional | 32.35% |
| Mutual fund holders | 22.48% |
| Individual stakeholders | 16.82% |